相似文献
1
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts.
Leukemia. 2024 Feb;38(2):389-392. doi: 10.1038/s41375-024-02143-8. Epub 2024 Jan 23.
2
Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.
J Hematol Oncol. 2025 Jan 16;18(1):7. doi: 10.1186/s13045-024-01657-z.
3
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
J Cancer Res Clin Oncol. 2016 Jan;142(1):317-24. doi: 10.1007/s00432-015-2050-y. Epub 2015 Sep 30.
4
A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly.
Clin Ther. 2011 Mar;33(3):254-79. doi: 10.1016/j.clinthera.2011.04.004.
5
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission.
Future Oncol. 2025 Jan;21(1):73-81. doi: 10.1080/14796694.2024.2433935. Epub 2024 Nov 28.
6
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years.
Cancer Res Commun. 2025 Jul 1;5(7):1129-1139. doi: 10.1158/2767-9764.CRC-25-0091.
7
Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.
Clin Exp Med. 2023 Jun;23(2):219-227. doi: 10.1007/s10238-021-00784-y. Epub 2022 Jan 23.
8
A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Acta Oncol. 2001;40(2-3):231-52. doi: 10.1080/02841860151116321.
9
Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML).
J Cancer Res Clin Oncol. 2014 Aug;140(8):1391-7. doi: 10.1007/s00432-014-1666-7. Epub 2014 Apr 12.
10
Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.
Ann Hematol. 2018 Jul;97(7):1115-1153. doi: 10.1007/s00277-018-3304-y. Epub 2018 Apr 21.
引用本文的文献
1
[Mitoxantrone hydrochloride liposome combined with cytarabine for treating pediatric acute myeloid leukemia with RUNX1∷MTG16 fusion gene: a case report and literature review].
Zhonghua Xue Ye Xue Za Zhi. 2024 Dec 14;45(12):1134-1137. doi: 10.3760/cma.j.cn121090-20240805-00289.
2
Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment.
Front Pharmacol. 2024 Aug 5;15:1409210. doi: 10.3389/fphar.2024.1409210. eCollection 2024.
本文引用的文献
1
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
2
Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.
J Clin Oncol. 2022 Mar 10;40(8):847-854. doi: 10.1200/JCO.21.01548. Epub 2021 Dec 10.
3
The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses.
Blood Rev. 2021 Jul;48:100806. doi: 10.1016/j.blre.2021.100806. Epub 2021 Jan 29.
4
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
J Clin Oncol. 2020 Oct 20;38(30):3506-3517. doi: 10.1200/JCO.20.00572. Epub 2020 Jul 20.
5
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Leukemia. 2020 Mar;34(3):671-681. doi: 10.1038/s41375-019-0704-5. Epub 2020 Jan 8.
6
Treatment practice and outcomes in mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals.
Leuk Lymphoma. 2020 Apr;61(4):848-854. doi: 10.1080/10428194.2019.1691192. Epub 2019 Nov 21.
7
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.
Blood. 2013 Aug 22;122(8):1384-94. doi: 10.1182/blood-2013-04-496596. Epub 2013 Jul 9.
8
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.
Leukemia. 2013 Jan;27(1):75-81. doi: 10.1038/leu.2012.229. Epub 2012 Aug 14.
9
Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.
Blood. 2010 Oct 7;116(14):2420-8. doi: 10.1182/blood-2010-05-285387. Epub 2010 Jun 10.
10
Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.
J Clin Oncol. 2010 Apr 1;28(10):1766-71. doi: 10.1200/JCO.2009.25.1066. Epub 2010 Feb 16.
Zotero 插件